Reversal of Rivaroxaban-Associated Bleeding
NEJM Journal Watch（2018）
摘要
Rivaroxaban, an inhibitor of clotting factor Xa, is associated with an annual major bleeding rate of 3.6%. A specific reversal agent is not yet
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要